JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB85603

Recombinant Human Cdk9 protein

Be the first to review this product! Submit a review

|

(1 Publication)

Recombinant Human Cdk9 protein is a Human Full Length protein, expressed in Baculovirus infected Sf9 cells, with >85%, suitable for SDS-PAGE, WB.

View Alternative Names

CDC2L4, TAK, CDK9, Cyclin-dependent kinase 9, C-2K, Cell division cycle 2-like protein kinase 4, Cell division protein kinase 9, Serine/threonine-protein kinase PITALRE, Tat-associated kinase complex catalytic subunit

2 Images
Sandwich ELISA - Recombinant Human Cdk9 protein (AB85603)
  • sELISA

Unknown

Sandwich ELISA - Recombinant Human Cdk9 protein (AB85603)

Standard Curve for Cdk9 (Analyte : Cdk9 protein (Tagged) (ab85603)); dilution range 1pg/ml to 1μg/ml using Capture Antibody Mouse monoclonal to Cdk9 (ab76873) at 5μg/ml and Detector Antibody Rabbit polyclonal to Cdk9 (ab38840) at 0.5μg/ml.

SDS-PAGE - Recombinant Human Cdk9 protein (AB85603)
  • SDS-PAGE

Unknown

SDS-PAGE - Recombinant Human Cdk9 protein (AB85603)

SDS-PAGE showing ab85603 at approximately 68kDa.

Key facts

Purity

>85% Densitometry

Expression system

Baculovirus infected Sf9 cells

Tags

GST tag N-Terminus

Applications

SDS-PAGE, WB

applications

Biologically active

No

Accession

P50750

Animal free

No

Carrier free

No

Species

Human

Storage buffer

pH: 7.5 Constituents: 25% Glycerol (glycerin, glycerine), 0.79% Tris HCl, 0.29% Sodium chloride, 0.00385% (R*,R*)-1,4-Dimercaptobutan-2,3-diol, 0.00292% EDTA, 0.00174% PMSF

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Sequence info

[{"sequence":"","proteinLength":"Full Length","predictedMolecularWeight":null,"actualMolecularWeight":null,"aminoAcidEnd":0,"aminoAcidStart":0,"nature":"Recombinant","expressionSystem":null,"accessionNumber":"P50750","tags":[{"tag":"GST","terminus":"N-Terminus"}]}]

Properties and storage information

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-80°C
Appropriate long-term storage conditions
-80°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
False

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Cyclin-dependent kinase 9 (Cdk9) is a serine/threonine protein kinase involved in regulating transcription elongation. It is often referred to as part of the positive transcription elongation factor b (P-TEFb) complex. Cdk9 partners with cyclin T1 T2 or K to form this complex allowing it to phosphorylate the carboxyl-terminal domain (CTD) of RNA polymerase II. The molecular weight of Cdk9 is around 42 kDa. This protein is ubiquitously expressed found in many tissues including the heart liver and brain reflecting its important role.
Biological function summary

Cdk9 functions as a central component of transcriptional processes. It is essential for the transition of RNA polymerase II from the initiation phase to productive elongation. As part of the P-TEFb complex Cdk9 targets negative elongation factors helping relieve their inhibition. This regulation is especially important in the control of genes with strong promoter proximally paused polymerase. By doing so Cdk9 controls the expression of several genes involved in cell growth differentiation and response to stress.

Pathways

Cdk9 plays a significant role in transcription and signal transduction pathways. One important pathway is the NF-κB signaling where Cdk9 regulates the transcription of NF-κB target genes involved in immune response. Another significant pathway is the heat shock response where Cdk9 enhances the expression of heat shock proteins helping cells deal with stress. In both pathways it cooperates with other proteins like cyclins and negative elongation factors illustrating its interconnected role in cellular function.

Cdk9 has been linked to several conditions most notably cancer and cardiac hypertrophy. Its overactivation can lead to increased transcription of genes involved in proliferation making it a focus for cancer research. Cdk9 is also implicated in cardiac hypertrophy where its activity affects gene expression that can exacerbate the condition. Researchers study its interaction with other proteins such as THZ1 a Cdk9 inhibitor to explore potential therapeutic avenues.

Specifications

Form

Liquid

Additional notes

Affinity purified.

General info

Function

Protein kinase involved in the regulation of transcription (PubMed : 10574912, PubMed : 10757782, PubMed : 11145967, PubMed : 11575923, PubMed : 11809800, PubMed : 11884399, PubMed : 14701750, PubMed : 16109376, PubMed : 16109377, PubMed : 20930849, PubMed : 28426094, PubMed : 29335245). Member of the cyclin-dependent kinase pair (CDK9/cyclin-T) complex, also called positive transcription elongation factor b (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAP II) POLR2A, SUPT5H and RDBP (PubMed : 10574912, PubMed : 10757782, PubMed : 11145967, PubMed : 11575923, PubMed : 11809800, PubMed : 11884399, PubMed : 14701750, PubMed : 16109376, PubMed : 16109377, PubMed : 20930849, PubMed : 28426094, PubMed : 30134174). This complex is inactive when in the 7SK snRNP complex form (PubMed : 10574912, PubMed : 10757782, PubMed : 11145967, PubMed : 11575923, PubMed : 11809800, PubMed : 11884399, PubMed : 14701750, PubMed : 16109376, PubMed : 16109377, PubMed : 20930849, PubMed : 28426094). Phosphorylates EP300, MYOD1, RPB1/POLR2A and AR and the negative elongation factors DSIF and NELFE (PubMed : 10912001, PubMed : 11112772, PubMed : 12037670, PubMed : 20081228, PubMed : 20980437, PubMed : 21127351, PubMed : 9857195). Regulates cytokine inducible transcription networks by facilitating promoter recognition of target transcription factors (e.g. TNF-inducible RELA/p65 activation and IL-6-inducible STAT3 signaling) (PubMed : 17956865, PubMed : 18362169). Promotes RNA synthesis in genetic programs for cell growth, differentiation and viral pathogenesis (PubMed : 10393184, PubMed : 11112772). P-TEFb is also involved in cotranscriptional histone modification, mRNA processing and mRNA export (PubMed : 15564463, PubMed : 19575011, PubMed : 19844166). Modulates a complex network of chromatin modifications including histone H2B monoubiquitination (H2Bub1), H3 lysine 4 trimethylation (H3K4me3) and H3K36me3; integrates phosphorylation during transcription with chromatin modifications to control co-transcriptional histone mRNA processing (PubMed : 15564463, PubMed : 19575011, PubMed : 19844166). The CDK9/cyclin-K complex has also a kinase activity towards CTD of RNAP II and can substitute for CDK9/cyclin-T P-TEFb in vitro (PubMed : 21127351). Replication stress response protein; the CDK9/cyclin-K complex is required for genome integrity maintenance, by promoting cell cycle recovery from replication arrest and limiting single-stranded DNA amount in response to replication stress, thus reducing the breakdown of stalled replication forks and avoiding DNA damage (PubMed : 20493174). In addition, probable function in DNA repair of isoform 2 via interaction with KU70/XRCC6 (PubMed : 20493174). Promotes cardiac myocyte enlargement (PubMed : 20081228). RPB1/POLR2A phosphorylation on 'Ser-2' in CTD activates transcription (PubMed : 21127351). AR phosphorylation modulates AR transcription factor promoter selectivity and cell growth. DSIF and NELF phosphorylation promotes transcription by inhibiting their negative effect (PubMed : 10912001, PubMed : 11112772, PubMed : 9857195). The phosphorylation of MYOD1 enhances its transcriptional activity and thus promotes muscle differentiation (PubMed : 12037670). Catalyzes phosphorylation of KAT5, promoting KAT5 recruitment to chromatin and histone acetyltransferase activity (PubMed : 29335245).

Sequence similarities

Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily.

Post-translational modifications

Autophosphorylation at Thr-186, Ser-347, Thr-350, Ser-353, Thr-354 and Ser-357 triggers kinase activity by promoting cyclin and substrate binding (e.g. HIV TAT) upon conformational changes. Thr-186 phosphorylation requires the calcium Ca(2+) signaling pathway, including CaMK1D and calmodulin. This inhibition is relieved by Thr-29 dephosphorylation. However, phosphorylation at Thr-29 is inhibitory within the HIV transcription initiation complex. Phosphorylation at Ser-175 inhibits kinase activity. Can be phosphorylated on either Thr-362 or Thr-363 but not on both simultaneously (PubMed:18566585).. Dephosphorylation of Thr-186 by PPM1A and PPM1B blocks CDK9 activity and may lead to CDK9 proteasomal degradation. However, PPP1CA-mediated Thr-186 dephosphorylation is required to release P-TEFb from its inactive P-TEFb/7SK snRNP complex. Dephosphorylation of C-terminus Thr and Ser residues by protein phosphatase-1 (PP1) triggers CDK9 activity, contributing to the activation of HIV-1 transcription.. N6-acetylation of Lys-44 promotes kinase activity, whereas acetylation of both Lys-44 and Lys-48 mediated by PCAF/KAT2B and GCN5/KAT2A reduces kinase activity (PubMed:17452463, PubMed:18250157). The acetylated form associates with PML bodies in the nuclear matrix and with the transcriptionally silent HIV-1 genome; deacetylated upon transcription stimulation (PubMed:17452463, PubMed:18250157). Deacetylated by SIRT7, promoting the kinase activity and subsequent 'Ser-2' phosphorylation of the C-terminal domain (CTD) of RNA polymerase II (PubMed:28426094).. Polyubiquitinated and thus activated by UBR5. This ubiquitination is promoted by TFIIS/TCEA1 and favors 'Ser-2' phosphorylation of RPB1/POLR2A CTD.

Subcellular localisation

Nucleus

Product protocols

Target data

Protein kinase involved in the regulation of transcription (PubMed : 10574912, PubMed : 10757782, PubMed : 11145967, PubMed : 11575923, PubMed : 11809800, PubMed : 11884399, PubMed : 14701750, PubMed : 16109376, PubMed : 16109377, PubMed : 20930849, PubMed : 28426094, PubMed : 29335245). Member of the cyclin-dependent kinase pair (CDK9/cyclin-T) complex, also called positive transcription elongation factor b (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAP II) POLR2A, SUPT5H and RDBP (PubMed : 10574912, PubMed : 10757782, PubMed : 11145967, PubMed : 11575923, PubMed : 11809800, PubMed : 11884399, PubMed : 14701750, PubMed : 16109376, PubMed : 16109377, PubMed : 20930849, PubMed : 28426094, PubMed : 30134174). This complex is inactive when in the 7SK snRNP complex form (PubMed : 10574912, PubMed : 10757782, PubMed : 11145967, PubMed : 11575923, PubMed : 11809800, PubMed : 11884399, PubMed : 14701750, PubMed : 16109376, PubMed : 16109377, PubMed : 20930849, PubMed : 28426094). Phosphorylates EP300, MYOD1, RPB1/POLR2A and AR and the negative elongation factors DSIF and NELFE (PubMed : 10912001, PubMed : 11112772, PubMed : 12037670, PubMed : 20081228, PubMed : 20980437, PubMed : 21127351, PubMed : 9857195). Regulates cytokine inducible transcription networks by facilitating promoter recognition of target transcription factors (e.g. TNF-inducible RELA/p65 activation and IL-6-inducible STAT3 signaling) (PubMed : 17956865, PubMed : 18362169). Promotes RNA synthesis in genetic programs for cell growth, differentiation and viral pathogenesis (PubMed : 10393184, PubMed : 11112772). P-TEFb is also involved in cotranscriptional histone modification, mRNA processing and mRNA export (PubMed : 15564463, PubMed : 19575011, PubMed : 19844166). Modulates a complex network of chromatin modifications including histone H2B monoubiquitination (H2Bub1), H3 lysine 4 trimethylation (H3K4me3) and H3K36me3; integrates phosphorylation during transcription with chromatin modifications to control co-transcriptional histone mRNA processing (PubMed : 15564463, PubMed : 19575011, PubMed : 19844166). The CDK9/cyclin-K complex has also a kinase activity towards CTD of RNAP II and can substitute for CDK9/cyclin-T P-TEFb in vitro (PubMed : 21127351). Replication stress response protein; the CDK9/cyclin-K complex is required for genome integrity maintenance, by promoting cell cycle recovery from replication arrest and limiting single-stranded DNA amount in response to replication stress, thus reducing the breakdown of stalled replication forks and avoiding DNA damage (PubMed : 20493174). In addition, probable function in DNA repair of isoform 2 via interaction with KU70/XRCC6 (PubMed : 20493174). Promotes cardiac myocyte enlargement (PubMed : 20081228). RPB1/POLR2A phosphorylation on 'Ser-2' in CTD activates transcription (PubMed : 21127351). AR phosphorylation modulates AR transcription factor promoter selectivity and cell growth. DSIF and NELF phosphorylation promotes transcription by inhibiting their negative effect (PubMed : 10912001, PubMed : 11112772, PubMed : 9857195). The phosphorylation of MYOD1 enhances its transcriptional activity and thus promotes muscle differentiation (PubMed : 12037670). Catalyzes phosphorylation of KAT5, promoting KAT5 recruitment to chromatin and histone acetyltransferase activity (PubMed : 29335245).
See full target information CDK9

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

eLife 8: PubMed30652970

2019

TRIM28 promotes HIV-1 latency by SUMOylating CDK9 and inhibiting P-TEFb.

Applications

Unspecified application

Species

Unspecified reactive species

Xiancai Ma,Tao Yang,Yuewen Luo,Liyang Wu,Yawen Jiang,Zheng Song,Ting Pan,Bingfeng Liu,Guangyan Liu,Jun Liu,Fei Yu,Zhangping He,Wanying Zhang,Jinyu Yang,Liting Liang,Yuanjun Guan,Xu Zhang,Linghua Li,Weiping Cai,Xiaoping Tang,Song Gao,Kai Deng,Hui Zhang
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com